Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL
Over the past decade, treatment recommendations for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have shifted from traditional chemoimmunotherapy to targeted therapies. Multiple new therapies are commercially available, and, in many cases, a lack of randomized clinical trial data makes selection of the optimal treatment for each patient challenging. Additionally, many patients continue to receive chemoimmunotherapy in the United States, suggesting a gap between guidelines and real-world practice. The Lymphoma Research Foundation convened a workshop comprising a panel of CLL/SLL experts in the United States to develop consensus recommendations for selection and sequencing of therapies for patients with CLL/SLL in the United States. Herein, the recommendations are compiled for use as a practical clinical guide for treating providers caring for patients with CLL/SLL, which complement existing guidelines by providing a nuanced discussion relating how our panel of CLL/SLL experts in the United States care for patients in a real-world environment.
Authors
- Douglas Edward Gladstone (ORCID: https://orcid.org/0000-0001-8484-2990)
- Marc Hoffmann (ORCID: https://orcid.org/0000-0003-2166-3105)
- Alan P Skarbnik (ORCID: https://orcid.org/0000-0002-1276-7546)
- Harsh Shah (ORCID: https://orcid.org/0000-0001-6054-5238)
- Jennifer R. Brown (ORCID: https://orcid.org/0000-0003-2040-4961)
- Catherine C. Coombs (ORCID: https://orcid.org/0000-0003-4656-7304)
- Deborah Marie Stephens (ORCID: https://orcid.org/0000-0001-9188-5008)
- Patrick K. Reville (ORCID: https://orcid.org/0000-0001-8433-3360)
- Ryan Jacobs (ORCID: https://orcid.org/0000-0001-7814-7959)
- Krish Patel (ORCID: https://orcid.org/0000-0002-2446-098X)
- Inhye E. Ahn (ORCID: https://orcid.org/0000-0003-3717-287X)
- Joanna Meehan Rhodes (ORCID: https://orcid.org/0000-0002-5068-9040)
- Andrew Lipsky (ORCID: https://orcid.org/0000-0002-7653-4792)
- Meghan C. Thompson (ORCID: https://orcid.org/0000-0003-1462-4802)
- Daniel A. Ermann (ORCID: https://orcid.org/0000-0001-9233-294X)
- Adam S. Kittai (ORCID: https://orcid.org/0000-0002-4891-6144)
- Jacqueline C. Barrientos (ORCID: https://orcid.org/0000-0001-6018-5535)
- Jacob D. Soumerai (ORCID: https://orcid.org/0000-0002-3062-6819)
Institutions
- Rutgers, The State University of New Jersey (US)
- University of North Carolina at Chapel Hill (US)
- Northwell Health (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- Hofstra University (US)
- University of California, Irvine (US)
- University of Utah (US)
- Columbia University Irving Medical Center (US)
- Huntsman Cancer Institute (US)
- Novant Health (US)
- Kettering University (US)
- Massachusetts General Hospital (US)
- Mount Sinai Medical Center (US)
- The University of Kansas Cancer Center (US)
- Levine Cancer Institute (US)
- Dana-Farber Cancer Institute (US)
- Tisch Hospital (US)
- University of Kansas Medical Center (US)
- Cancer Genetics (United States) (US)
- Sylvester Comprehensive Cancer Center (US)
- Rutgers Cancer Institute (US)
- Tisch Cancer Institute
- UNC Lineberger Comprehensive Cancer Center
- Wake Forest University (US)
Publication Details
- Journal
- Blood Advances
- Published
- 2024-11-19
- DOI
- https://doi.org/10.1182/bloodadvances.2024014474
- Citations
- 17
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 7.45
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Gilead Sciences
- Alexion Pharmaceuticals
- Celgene
- Jazz Pharmaceuticals
- TG Therapeutics
- MEI Pharma
- bluebird bio
- Adaptive Biotechnologies
- BeiGene
- Cardinal Health
- Moderna
- Seagen
- MorphoSys
- Grifols
- Genentech
- Kite Pharma
- Pharmacyclics
- Loxo Oncology